BOSTON--(BUSINESS WIRE)--Manifold Bio, a platform therapeutics company pioneering AI-guided drug discovery coupled with direct-to-vivo measurement, today announced a strategic research collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY). The partnership will apply Manifold's proprietary tissue-targeting shuttle portfolio and mDesign AI-driven in vivo discovery engine to create multiple next-generation BBB shuttles for the treatment of neurological and neurodegenerative d. ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Foundation Launches $22 Million Initiative to Improve Cardiovascular Care in the U.S. ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes. ...

Key Points The big near-term headwind for this drug maker is upcoming patent expirations. The company is working to address the issue, with a sizable acquisition that will advance its efforts in the diet drug space. Management has also been working with the U.S. government to better position itself for changing regulations. 10 stocks we like better than Pfizer › Pfizer (NYSE: PFE) is one of the oldest and most respected pharmaceutical companies in the world. The stock is out of favor right now, tr ...

Core Insights - The training course titled "Global Regulatory Requirements for Drug Safety & Pharmacovigilance" is aimed at pharmaceutical and biologic companies in the US and EU, focusing on product safety regulatory requirements [1][2]. Group 1: Training Course Overview - The course is designed to help companies understand the latest compliance expectations in pharmacovigilance to maintain product marketability [2]. - It emphasizes the importance of having adequate systems and processes for safety reporting to avoid significant consequences, including product recalls [2]. Group 2: Learning Objectives - Participants will learn about the regulatory requirements for drug safety, including the US, EU, and UK frameworks, and specific details regarding EU GVP modules [6]. - The course will cover the contents of the Pharmacovigilance System Master File (PSMF) and the requirements for quality oversight of drug safety [6]. - Key topics include signal management regulations, UK QPPV responsibilities, and penalties for non-compliance [6][8]. Group 3: Target Audience - The training is relevant for nearly all individuals involved in drug development and marketing, including executives with legal responsibilities for drug safety [5][6]. Group 4: Instructor Profile - The course will be led by Steve Jolley, a subject matter expert with 37 years of experience in drug safety and pharmacovigilance, who has worked with over 300 clients globally [10][12].

Key Points Pfizer has long been a solid dividend payer, having raised its dividend annually for 16 years. Its yield is high because the stock price has fallen in recent years. That has given it an appealing valuation. 10 stocks we like better than Pfizer › I can think of more than a few reasons why someone might want to invest in Pfizer (NYSE: PFE), the pharmaceutical giant. The best one, for me at the moment, is its huge dividend yield -- 7% as of Friday. Consider that the best high-yield bank s ...

Core Points - Kyowa Kirin International has appointed Julie Dehaene-Puype as President for the Region, effective November 1, 2025 [1] - Julie Dehaene-Puype succeeds Jeremy Morgan, who has been serving as President for the International Region since 2023 [1] - Jeremy Morgan will transition to an advisory role within the business following his tenure [1]

Group 1 - European companies are demonstrating remarkable adaptability to U.S. tariff barriers, with a Goldman Sachs portfolio of affected European stocks outperforming the market by approximately 6% in October, double the gain of the Stoxx Europe 600 index [1] - Major European firms like Hermès, Unilever, and Galderma Group AG attribute their better-than-expected performance and raised guidance to strong demand in the U.S. market [1][2] - The frequency of the term "tariff" in earnings calls is decreasing, indicating that corporate management's concerns about tariffs are diminishing [1] Group 2 - The U.S. market has become a key growth driver for many European companies, with Hermès reporting a 14.1% sales increase in its regional markets, and Unilever crediting strong North American demand for its sales performance [2] - Galderma raised its full-year guidance based on strong U.S. sales, while other companies like Haleon Plc and Stellantis also reported unexpected sales growth in North America [2] Group 3 - Companies are adapting to tariff challenges by cutting costs, adjusting production layouts, and increasing investments in the U.S. [3] - Pharmaceutical companies like Novartis and GSK are negotiating with the U.S. government for price reductions in exchange for future tariff exemptions, with AstraZeneca reaching an agreement in October [3] Group 4 - Despite overall optimism, the impact of tariffs is not uniform, with some companies like Rémy Cointreau and Pernod Ricard warning of weaker-than-expected recovery in specific markets [4] - Market sentiment is shifting towards the view that tariffs are manageable, although some analysts caution against premature conclusions regarding their impact [4][5]

We recently published 10 Stocks With Easy 20-40% Gains. Metsera Inc. (NASDAQ:MTSR) is one of the last week's best-performing stocks. Metsera saw its share prices jump by 20 percent week-on-week as investors gobbled up shares amid a billion-dollar bidding war between two pharmaceutical giants racing to gain a larger foothold in the booming weight-loss industry. This followed Novo Nordisk’s confirmation late last week that it submitted a new $8.5 billion offer to acquire Metsera Inc. (NASDAQ:MTSR), which w ...

We recently published 10 Stocks With Easy 20-40% Gains. Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of the last week's best-performing stocks. Travere Therapeutics soared by 25.3 percent week-on-week as investors took heart from a stellar earnings performance and cues that the company would kick off the last month of the year on a strong note. Based on its financial statement on Thursday, Travere Therapeutics, Inc. (NASDAQ:TVTX) swung to a net income of $25.7 million in the third quarter of the year ...